APPENDIX 3C
Quarter (a)Quarter (a)Quarter (a)Quarter (a)Quarter (e)Quarter
30-Sep-1831-Dec-1831-Mar-1930-Jun-1930-Sep-1931-Dec-191. Cash flows from operating activities
1.1 Receipts from customers
295,525 489,209 1,018,142 1,058,518 1,200,000 regression value1.2 Payments for
(a) research and development
-213,580 21,433 -232,311 -181,752 -170,000 co forecast(b) product manufacturing and operating costs
-341,393 -316,102 -127,602 -368,083 -210,000 co forecast(c) advertising and marketing
-3,270 -189,247 -170,891 -231,821 -80,000 co forecast(d) leased assets - -
----
(e) staff costs
-548,623 -597,808 -640,656 -728,645 -720,000 co forecast(f) administration and corporate costs
-585,250 -495,517 -382,037 -427,507 -370,000 co forecast1.3 Dividends received (see note 3)
----
1.4 Interest received
5,587 2,655 3,668 5,879 3,000 regression value1.5 Interest and other costs of finance paid - -
----
1.6 Income taxes paid - -
----
1.7 Government grants and tax incentives
401,826 -7,003 560,932
1.8 Other (provide details if material)
53,059 ---
1.9 Net cash from / (used in) operating activities
-937,119 -1,085,377 -524,684 -312,479 -347,000
2. Cash flows from investing activities
2.1 Payments to acquire:
(a) property, plant and equipment
-249,550 -221,100 -203,618 -176,541 -150,000 regression value(b) businesses (see item 10) - -
----
(c) investments - -
----
(d) intellectual property - -
----
(e) other non-current assets - -
----
2.2 Proceeds from disposal of:
----
(a) property, plant and equipment - -
----
(b) businesses (see item 10) - -
----
(c) investments - -
----
(d) intellectual property - -
----
(e) other non-current assets - -
----
2.3 Cash flows from loans to other entities - -
----
2.4 Dividends received (see note 3) - -
----
2.5 Other (provide details if material) - -
----
2.6 Net cash from / (used in) investing activities
-249,550 -221,100 -203,618 -176,541 -150,000
3. Cash flows from financing activities
3.1 Proceeds from issues of shares
-1,696,900 1,299,696 -9,852,597 App3B3.2 Proceeds from issue of convertible notes - -
----
3.3 Proceeds from exercise of share options
----
3.4 Transaction costs related to issues of shares, convertible notes or options--6,534 -80,720 -5,060 -90,000 guess3.5 Proceeds from borrowings - -
---500,000
3.6 Repayment of borrowings - -
-----500,000 why not3.7 Transaction costs related to loans and borrowings
----155,580
3.8 Dividends paid - -
----
3.9 Other (provide details if material) - -
----
3.10 Net cash from / (used in) financing activities
-1,690,366 1,218,976 339,360 9,262,597
4. Net increase / (decrease) in cash and cash equivalents for the period
4.1 Cash and cash equivalents at beginning of quarter/year to date
2,054,300 855,428 1,229,499 1,728,282 1,561,961
4.2 Net cash from / (used in) operating activities (item 1.9 above)
-937,119 -1,085,377 -524,684 -312,479 -347,000
4.3 Net cash from / (used in) investing activities (item 2.6 above)
-249,550 -221,100 -203,618 -176,541 -150,000
4.4 Net cash from / (used in) financing activities (item 3.10 above)
0 1,690,366 1,218,976 339,360 9,262,597
4.5 Effect of movement in exchange rates on cash held
-12,203 -9,818 8,109 -16,661 -10,000
4.6 Cash and cash equivalents at end of quarter
855,428 1,229,499 1,728,282 1,561,961 10,317,558
APPENDIX 3B
Shares Issued:
169,956,226182,077,076193,378,776193,378,776251,718,446252,068,44608-Nov-18
11,156,564
08-Nov-18
964,286
20-Feb-19
11,301,700
CR issue 47,750,000 raised $9,550,000 08-Aug-19
19,337,877
CR announced 2 Aug-19 08-Aug-19
28,412,123
Loan funded except 33,000 @ 30cents raised $9,900 CR 20-Sep-19
8,333,000
Ex options @22cents raised $292,967 25-Sep-19
1,331,670
Loan funded shares no CR 27-Sep-19
925,000
Loan funded shares no CR 4-Oct-19
350,000
Here is my questimate for the next.4C.I hope the amount of cash reflects need for production to meet new orders and not more marketing? Adjust with your estimate of quarter revenue. DYOR
- Forums
- ASX - By Stock
- Drone Media
APPENDIX 3CQuarter (a)Quarter (a)Quarter (a)Quarter (a)Quarter...
- There are more pages in this discussion • 420 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DRO (ASX) to my watchlist
(20min delay)
|
|||||
Last
87.5¢ |
Change
0.045(5.42%) |
Mkt cap ! $616.3M |
Open | High | Low | Value | Volume |
83.5¢ | 88.0¢ | 81.5¢ | $9.089M | 10.64M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 68605 | 87.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
87.5¢ | 120128 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 68605 | 0.870 |
3 | 27226 | 0.865 |
6 | 452235 | 0.860 |
4 | 28150 | 0.855 |
8 | 219483 | 0.850 |
Price($) | Vol. | No. |
---|---|---|
0.875 | 120128 | 3 |
0.880 | 250732 | 9 |
0.885 | 24825 | 3 |
0.890 | 32900 | 6 |
0.895 | 26422 | 4 |
Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
86.5¢ |
  |
Change
0.045 ( 4.48 %) |
|||
Open | High | Low | Volume | ||
83.5¢ | 88.0¢ | 81.5¢ | 4222438 | ||
Last updated 15.59pm 06/05/2024 ? |
Featured News
DRO (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online